Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 1/20 | 0.49 |
| ▸ | F3 | P13726 | 1/20 | 0.49 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.49 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.49 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.49 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.49 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.49 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 5/20 | 0.46 |
| ▸ | CA2 | P00918 | 5/20 | 0.46 |
| ▸ | CA9 | Q16790 | 5/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.41 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.41 |
| ▸ | SLC28A3 | Q9HAS3 | 2/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Niacinamide SCHEMBL20398298 | 0.90 | F7 (0.55) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL28136690 | 0.86 | F7 (0.51) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL17315028 | 0.85 | F7 (0.50) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL21571784 | 0.85 | F7 (0.50) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL28137384 | 0.85 | F7 (0.50) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL17315040 | 0.85 | F7 (0.47) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL30498617 | 0.83 | F7 (0.48) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL28184048 | 0.83 | F7 (0.48) | F7F3SARM1SIRT2SIRT6 | |
| Ribose (Furanose) SCHEMBL338518 | 0.83 | F7 (0.59) | F7F3SARM1SIRT2SIRT6 | |
| Ribose (Furanose) SCHEMBL14321532 | 0.83 | F7 (0.59) | F7F3SARM1SIRT2SIRT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216412-A1 | OXIDIZED NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD+) PRECURSOR TREATMENT FOR HEART FAILURE ALLEVIATION INDEPENDENT OF MITOCHONDRIAL PROTEIN DEACETYLATION | UNIVERSITY OF WASHINGTON (US) | 2024-07-04 | — | — | US | disclosed |
| US-20230263817-A1 | HIGH DOSE NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) PRECURSOR REGIMENS FOR REDUCTION OF INFLAMMATION IN HUMAN PATIENTS WITH PREEXISTING INFLAMMATION | UNIVERSITY OF WASHINGTON (US) | 2023-08-24 | — | — | US | disclosed |
| US-11633414-B2 | Nicotinoyl riboside compositions and methods of use | CORNELL UNIVERSITY (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220125814-A1 | CANCER COMBINATION THERAPIES UTILIZING A NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITOR IN COMBINATION WITH A NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY PRECURSOR | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2022-04-28 | — | — | US | disclosed |
| WO-2022047182-A1 | HIGH DOSE NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) PRECURSOR REGIMENS FOR REDUCTION OF INFLAMMATION IN HUMAN PATIENTS WITH PREEXISTING INFLAMMATION | UNIVERSITY OF WASHINGTON (US) | 2022-03-03 | — | — | WO | disclosed |
| US-20210388018-A1 | METHYL AND ETHYL NICOTINATE-RIBOSIDE-5-PHOSPHATES, PREPARATION THEREOF AND METHODS OF USE THEREOF | CORNELL UNIVERSITY (US) | 2021-12-16 | — | — | US | disclosed |
| US-20210353657-A1 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | CORNELL UNIVERSITY (US) | 2021-11-18 | — | — | US | disclosed |
| US-11077129-B2 | Nicotinoyl riboside compositions and methods of use | CORNELL UNIVERSITY (US) | 2021-08-03 | — | — | US | disclosed |
| EP-3730507-A1 | NICOTINOYL RIBOSIDE AND NICOTINAMIDE RIBOSIDE COMPOSITIONS FOR USE IN REDUCING TOXICITY INDUCED BY HMG-COA REDUCTASE INHIBITORS | Cornell Research Foundation, Inc. (US) | 2020-10-28 | — | — | EP | disclosed |
| WO-2020191359-A1 | CANCER COMBINATION THERAPIES UTILIZING A NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITOR IN COMBINATION WITH A NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY PRECURSOR | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2020-09-24 | — | — | WO | disclosed |
| EP-1957086-B1 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | CORNELL RES FOUNDATION INC (US) | 2018-05-02 | — | — | EP | disclosed |
| US-20160310517-A1 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | CORNELL UNIVERSITY | 2016-10-27 | — | — | US | disclosed |
| US-9321797-B2 | Nicotinoyl riboside compositions and methods of use | CORNELL UNIVERSITY (US) | 2016-04-26 | — | — | US | disclosed |
| US-9000147-B2 | Nicotyl riboside compositions and methods of use | CORNELL UNIVERSITY (US) | 2015-04-07 | — | — | US | disclosed |
| US-20150072950-A1 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | CORNELL UNIVERSITY | 2015-03-12 | — | — | US | disclosed |
| US-20120172584-A1 | NICOTYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | CORNELL UNIVERSITY (US) | 2012-07-05 | — | — | US | disclosed |
| US-8106184-B2 | Nicotinoyl riboside compositions and methods of use | CORNELL UNIVERSITY (US) | 2012-01-31 | — | — | US | disclosed |
| EP-1957086-A2 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | CORNELL RESEARCH FOUNDATION, INC. (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007061798-A2 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | CORNELL RESEARCH FOUNDATION, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070117765-A1 | Nicotinoyl riboside compositions and methods of use | CORNELL RESEARCH FOUNDATION INC. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172584-A1 | NICOTYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | NNT, NAMPT, NAPRT | F7 4847/4885F3 2113/4885SARM1 14/4885 |
| US-11077129-B2 | Nicotinoyl riboside compositions and methods of use | NNT, CD38, NAMPT | F7 4789/4885F3 2117/4885SARM1 13/4885 |
| US-20230263817-A1 | HIGH DOSE NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) PRECURSOR REGIMENS FOR REDUCTION OF INFLAMMATION IN HUMAN PATIENTS WITH PREEXISTING INFLAMMATION | NAMPT, NNT, NQO1 | F7 3362/4885F3 1095/4885SARM1 8/4885 |
| US-20160310517-A1 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | NADK, NNT, CD38 | F7 4644/4885F3 2590/4885SARM1 9/4885 |
| US-20070117765-A1 | Nicotinoyl riboside compositions and methods of use | NNT, CD38, NAMPT | F7 4789/4885F3 2117/4885SARM1 13/4885 |
| US-20220125814-A1 | CANCER COMBINATION THERAPIES UTILIZING A NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITOR IN COMBINATION WITH A NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY PRECURSOR | NAMPT, NADK, NNT | F7 4804/4885F3 3364/4885SARM1 12/4885 |
| US-20210353657-A1 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | NNT, CD38, NAMPT | F7 4789/4885F3 2117/4885SARM1 13/4885 |
| US-20150072950-A1 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | NNT, CD38, NAMPT | F7 4789/4885F3 2117/4885SARM1 13/4885 |
| US-20210388018-A1 | METHYL AND ETHYL NICOTINATE-RIBOSIDE-5-PHOSPHATES, PREPARATION THEREOF AND METHODS OF USE THEREOF | NNT, NME4, NADK | F7 2322/4885F3 1652/4885SARM1 20/4885 |
| US-11633414-B2 | Nicotinoyl riboside compositions and methods of use | NNT, CD38, NAMPT | F7 4789/4885F3 2117/4885SARM1 13/4885 |
| US-20240216412-A1 | OXIDIZED NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD+) PRECURSOR TREATMENT FOR HEART FAILURE ALLEVIATION INDEPENDENT OF MITOCHONDRIAL PROTEIN DEACETYLATION | NAMPT, SIRT3, NDUFAB1 | F7 4860/4885F3 2491/4885SARM1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.